$TRUMP
$XAU
Why Zealand Pharma shares are declining
Zealand Pharma shares fell 11.7% today after its partner Boehringer Ingelheim announced results from the Phase 3 SYNCHRONIZE-2 trial for survodutide, a dual agonist of the glucagon/GLP-1 receptors, during the 66th annual meeting of the European Association for the Study of Diabetes in Milan—while the data were published simultaneously in the New England Journal of Medicine.
The trial met both of its co-primary endpoints: patients achieved an average body-weight reduction of 13.1% compared with 3.1% in the placebo group over 76 weeks, while up to 79.3% of patients who received survodutide lost at least 5% of their body weight.#KoreaProposesTokenizingStocksAndBonds #MicronBeatsEarningsLiftsGuidance #BitcoinClears$85200 #AltcoinSeasonIndexHoldsAbove60For5Days #AltcoinSeasonIndexHoldsAbove60For5Days
$XAU
Why Zealand Pharma shares are declining
Zealand Pharma shares fell 11.7% today after its partner Boehringer Ingelheim announced results from the Phase 3 SYNCHRONIZE-2 trial for survodutide, a dual agonist of the glucagon/GLP-1 receptors, during the 66th annual meeting of the European Association for the Study of Diabetes in Milan—while the data were published simultaneously in the New England Journal of Medicine.
The trial met both of its co-primary endpoints: patients achieved an average body-weight reduction of 13.1% compared with 3.1% in the placebo group over 76 weeks, while up to 79.3% of patients who received survodutide lost at least 5% of their body weight.#KoreaProposesTokenizingStocksAndBonds #MicronBeatsEarningsLiftsGuidance #BitcoinClears$85200 #AltcoinSeasonIndexHoldsAbove60For5Days #AltcoinSeasonIndexHoldsAbove60For5Days
